99mTc-DARPinG3 SPECT/CT for Non-invasive HER2-AX in Breast Cancer With Metastatic Lymph Nodes Before Targeted Therapy

Breast Cancer Female Clinical Trial

Official title:

SPECT/CT Imaging of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Primary Tumour and Metastatic Axillary Lymph Nodes Using Technetium-99m-labelled DARPinG3 Molecule-based.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05695859
• Other study ID #: 99mTc-DARPinG3 breast cancer
• Status: Completed
• Start date: December 20, 2022
• Est. completion date: December 1, 2023

Study information

• Verified date: February 2024
• Source: Tomsk National Research Medical Center of the Russian Academy of Sciences
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

An open-label, single center study with 99mTc-DARPinG3 SPECT/CT and biopsies of primary tumour and metastatic lymph nodes in breast cancer patients, where the primary endpoint of the study is to find out the correlation between the HER2 expression measured by 99mTc-DARPinG3 SPECT/CT and standard histopathology from relevant tumor and lymph node biopsies.

Description:

Overall goal of the project: To determine HER2 expression level in primary breast cancer and axillary lymph node metastases before chemo/targeted therapy.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: December 1, 2023
• Est. primary completion date: December 1, 2023
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Subject is > 18 years of age

• Diagnosis of primary breast cancer with lymph node metastases

• Availability of results from HER2 status previously determined on material from the primary tumor and metastatic LN, either a. HER2-positive, defined as a DAKO HercepTest™ score of 3+ or FISH positive or b. HER2-negative, defined as a DAKO HercepTest™ score of 0 or 1+; or else if 2+ then FISH negative

• Hematological, liver and renal function test results within the following limits:

White blood cell count: > 2.0 x 109/L; Hemoglobin: > 80 g/L; Platelets: > 50.0 x 109/L; ALT, ALP, AST: =< 5.0 times Upper Limit of Normal; Bilirubin =< 2.0 times Upper Limit of Normal; Serum creatinine: Within Normal Limits.

• A negative pregnancy test for all patients of childbearing potential. Sexually active women of childbearing potential participating in the study must use a medically acceptable form of contraception for at least 30 days after study termination

• Subject is capable to undergo the diagnostic investigations to be performed in the study

• Informed consent

Exclusion Criteria:

• Any system therapy (chemo-/targeted therapy)

• Second, non-breast malignancy

• Active current autoimmune disease or history of autoimmune disease

• Active infection or history of severe infection within the previous 3 months (if clinically relevant at screening) 4. Known HIV positive or chronically active hepatitis B or C

• Administration of other investigational medicinal product within 30 days of screening

• Ongoing toxicity > grade 2 from previous standard or investigational therapies, according to US National Cancer Institute's

Related Conditions & MeSH terms

• Breast Cancer Female
• Breast Neoplasms

Intervention

Drug:
• 99mTc-DARPinG3 SPECT/CT
One single injection of 99mTc-DARPinG3, followed by gamma camera imaging 4 hours after injection

Locations

Country	Name	City	State
Russian Federation	Russia Tomsk NRMC	Tomsk

Sponsors (2)

Lead Sponsor	Collaborator
Tomsk National Research Medical Center of the Russian Academy of Sciences	Uppsala University

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	SPECT/CT-based 99mTc-DARPinG3 uptake in tumor lesions	SPECT/CT-based 99mTc-DARPinG3 uptake value in tumor lesions (counts)/SUV of 99mTc-DARPinG3 focal uptake coinciding with tumor lesions is assessed using SPECT/CT at 4 hours after injection and measured in counts and SUV	4 hours
Primary	SPECT/CT-based 99mTc-DARPinG3 uptake value in metastatic lymph nodes	SPECT/CT-based 99mTc-DARPinG3 uptake value in metastatic lymph nodes (counts)/SUV of 99mTc-DARPinG3 focal uptake coinciding with tumor lesions is assessed using SPECT/CT at 4 hours after injection and measured in counts and SUV	4 hours
Primary	Tumor-to-background ratio (SPECT)	The SPECT-based tumor-to-background ratio will be calculated as follows: the value of 99mTc-DARPinG3 uptake coinciding with tumor lesions (counts/SUV) will be divided by the value of 99mTc-DARPinG3 uptake coinciding with the regions without pathological findings (counts/SUV)	4 hours
Primary	LN-to-background LN ratio (SPECT)	The SPECT-based LN-to-background LN ratio will be calculated as follows: the value of 99mTc-DARPinG3 uptake coinciding with LN lesions (counts/SUV) will be divided by the value of 99mTc-DARPinG3 uptake coinciding with the regions without pathological findings (counts/SUV)	4 hours
Secondary	Morphological and immunohistochemical verification of 99mTc-DARPinG3 accumulation	Comparison of the 99mTc-DARPinG3 accumulation in the primary tumor and metastatic lymph nodes with the results of morphological and immunohistochemical studies	4 hours